Inhibition of DNA methylation by antisense oligonucleotide MG98 as cancer therapy - PubMed (original) (raw)
Review
Inhibition of DNA methylation by antisense oligonucleotide MG98 as cancer therapy
Robert J Amato. Clin Genitourin Cancer. 2007 Dec.
Abstract
Results of preclinical studies and clinical phase I/II trials suggest that the antisense oligodeoxynucleotide and DNA methyltransferase inhibitor MG98 can safely and effectively lead to reactivation of methylation silence tumor suppressor genes. It is possible that daily or continuous dosing of MG98 might be more active and less toxic than intermittent dosing. Combination of MG98 with other agents having completely different mechanisms of action seems reasonable. One clinical trial now under way is evaluating the use of MG98 in combination with interferon-alpha in patients with advanced renal cell carcinoma (RCC). Because of the current preclinical and clinical evidence, further trials of MG98 as therapy for RCC would be of interest.
Similar articles
- MG98, a second-generation DNMT1 inhibitor, in the treatment of advanced renal cell carcinoma.
Amato RJ, Stephenson J, Hotte S, Nemunaitis J, Bélanger K, Reid G, Martell RE. Amato RJ, et al. Cancer Invest. 2012 Jun;30(5):415-21. doi: 10.3109/07357907.2012.675381. Cancer Invest. 2012. PMID: 22571342 Clinical Trial. - Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors.
Plummer R, Vidal L, Griffin M, Lesley M, de Bono J, Coulthard S, Sludden J, Siu LL, Chen EX, Oza AM, Reid GK, McLeod AR, Besterman JM, Lee C, Judson I, Calvert H, Boddy AV. Plummer R, et al. Clin Cancer Res. 2009 May 1;15(9):3177-83. doi: 10.1158/1078-0432.CCR-08-2859. Epub 2009 Apr 21. Clin Cancer Res. 2009. PMID: 19383817 Clinical Trial. - A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia.
Klisovic RB, Stock W, Cataland S, Klisovic MI, Liu S, Blum W, Green M, Odenike O, Godley L, Burgt JV, Van Laar E, Cullen M, Macleod AR, Besterman JM, Reid GK, Byrd JC, Marcucci G. Klisovic RB, et al. Clin Cancer Res. 2008 Apr 15;14(8):2444-9. doi: 10.1158/1078-0432.CCR-07-1320. Clin Cancer Res. 2008. PMID: 18413836 Clinical Trial. - DNA methyltransferase inhibitors: old and new drugs for an epigenetic cancer therapy.
Brueckner B, Lyko F. Brueckner B, et al. Trends Pharmacol Sci. 2004 Nov;25(11):551-4. doi: 10.1016/j.tips.2004.09.004. Trends Pharmacol Sci. 2004. PMID: 15491775 Review. - DNA hypermethylation as a chemotherapy target.
Ren J, Singh BN, Huang Q, Li Z, Gao Y, Mishra P, Hwa YL, Li J, Dowdy SC, Jiang SW. Ren J, et al. Cell Signal. 2011 Jul;23(7):1082-93. doi: 10.1016/j.cellsig.2011.02.003. Epub 2011 Feb 21. Cell Signal. 2011. PMID: 21345368 Review.
Cited by
- The role of DNA methylation in aging, rejuvenation, and age-related disease.
Johnson AA, Akman K, Calimport SR, Wuttke D, Stolzing A, de Magalhães JP. Johnson AA, et al. Rejuvenation Res. 2012 Oct;15(5):483-94. doi: 10.1089/rej.2012.1324. Rejuvenation Res. 2012. PMID: 23098078 Free PMC article. Review. - Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.
Cheng Y, He C, Wang M, Ma X, Mo F, Yang S, Han J, Wei X. Cheng Y, et al. Signal Transduct Target Ther. 2019 Dec 17;4:62. doi: 10.1038/s41392-019-0095-0. eCollection 2019. Signal Transduct Target Ther. 2019. PMID: 31871779 Free PMC article. Review. - Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA.
Szczepanek J, Skorupa M, Jarkiewicz-Tretyn J, Cybulski C, Tretyn A. Szczepanek J, et al. Int J Mol Sci. 2023 Apr 13;24(8):7235. doi: 10.3390/ijms24087235. Int J Mol Sci. 2023. PMID: 37108398 Free PMC article. Review. - Cancer Biology, Epidemiology, and Treatment in the 21st Century: Current Status and Future Challenges From a Biomedical Perspective.
Piña-Sánchez P, Chávez-González A, Ruiz-Tachiquín M, Vadillo E, Monroy-García A, Montesinos JJ, Grajales R, Gutiérrez de la Barrera M, Mayani H. Piña-Sánchez P, et al. Cancer Control. 2021 Jan-Dec;28:10732748211038735. doi: 10.1177/10732748211038735. Cancer Control. 2021. PMID: 34565215 Free PMC article. - The Role of Epigenetics in the Progression of Clear Cell Renal Cell Carcinoma and the Basis for Future Epigenetic Treatments.
Angulo JC, Manini C, López JI, Pueyo A, Colás B, Ropero S. Angulo JC, et al. Cancers (Basel). 2021 Apr 25;13(9):2071. doi: 10.3390/cancers13092071. Cancers (Basel). 2021. PMID: 33922974 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources